Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 27, 2017updated 23 Oct 2017 12:32pm

ViewRay initiates clinical trial of MRIdian system for pancreatic cancer

US-based ViewRay has initiated a clinical trial to evaluate its MRIdian system to treat patients with locally advanced unresectable pancreatic cancer.

US-based ViewRay has initiated a clinical trial to evaluate its MRIdian system to treat patients with locally advanced unresectable pancreatic cancer.

MRIdian is a MRI-guided radiation therapy system being developed to identify, target and track the position and shape of soft-tissue tumours during radiation.

Cleared by the US Food and Drug Administration (FDA), the system combines MRI technology and radiation delivery with the firm’s software.

The multi-centre, prospective and single-arm trial is the first study launched by the firm’s Clinical Cooperative Think Tank (C2T2) group that includes MRIdian clinical users.

C2T2 has been established to collect data for the validation of MR-guided radiation therapy and to pursue new approaches to improving survival and quality of life for pancreatic cancer patients.

The combination of live MR guidance and daily online treatment adaptation is expected to provide a new opportunity to treat cancer.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
“According to the results, the combination of MR image-guided stereotactic dosing regimens and daily online adaptation demonstrated prolonged survival and low toxicity.”

C2T2 has reported positive results from a trial performed in 42 patients with locally advanced pancreatic cancer at US Universities, including Washington University, University of California, Los Angeles (UCLA), University of Wisconsin, and VU University Medical Center (VUmc).

According to the results, the combination of MR image-guided stereotactic dosing regimens and daily online adaptation demonstrated prolonged survival and low toxicity.

Trial’s lead investigator Parag Parikh said: “Based on compelling early evidence on the use of MRIdian to treat locally advanced pancreatic cancer, we are eager to further explore the system’s capabilities and associated toxicity, local control, and patient outcomes.

“We believe MRIdian’s excellent real-time visualisation of organs at risk within the abdomen and its daily treatment adaptation will allow us to deliver higher, more effective doses to the target while minimising impact on the normal surrounding tissue.”


Image: MRIdian radiation therapy system. Photo: courtesy of ViewRay.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU